Claims
- 1. A compound having the formula
- 2. A compound of claim 1 wherein m is 2.
- 3. A compound of claim 1 wherein n is 1.
- 4. A compound of claim 1 wherein R1 is
- 5. The compound of claim 1 wherin R2 is C1-6 alkyl, C2-6 alkenyl or C3-7 cycloalkyl.
- 6. A compound of claim 5 wherein R2 is ethyl or vinyl.
- 7. The compound of claim 1 wherein R3 is C1-8 alkyl optionally substituted with C6 aryl, C1-6 alkoxy, carboxy, hydroxy, aryloxy, C7-14 alkylaryloxy, C2-6 alkylester, C8-15 alkylarylester; C3-12 alkenyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl.
- 8. The compound of claim 7 wherein R3 is C1-8 alkyl optionally substituted with C1-6 alkoxy; or C3-7 cycloalkyl.
- 9. A compound of claim 1 wherein R3 is C1-6 alkyl.
- 10. The compound of claim 9 wherein R3 is t-butyl.
- 11. A compound of claim 1 wherein m is 2, n is 1 and R2 is ethyl.
- 12. A compound of claim 1 wherein m is 2, n is 1 and R2 is vinyl.
- 13. The compound of claim 1 wherein Y is H.
- 14. The compound of claim 1 wherein B is H, C1-6 alkyl, R4—(C═O)—, R4O(C═O)—, R4—N(R5)—C(═O)—, R4—N(R5)—C(═S)—, R4SO2—, or R4—N(R5)—SO2—.
- 15. The compound of claim 14 wherein B is R4—(C═O)—, R4O(C═O)—, or R4—N(R5)—C(═O)—.
- 16. The compound of claim 15 wherein B is R4O(C═O)— and R4 is C1-6 alkyl.
- 17. The compound of claim 1 wherein R4 is (i) C1-10 alkyl optionally substituted with phenyl, carboxyl, C1-6 alkanoyl, 1-3 halogen, hydroxy, C1-6 alkoxy; (ii) C3-7 cycloalkyl, C3-7 cycloalkoxy, or C4-10 alkylcycloalklyl; or (iii) C6-10 aryl or C7-16 arylalkyl, each optionally substituted with C1-6 alkyl or halogen.
- 18. The compound of claim 14 wherein R4 is (i) C1-10 alkyl optionally substituted with 1-3 halogen or C1-6 alkoxy; or (ii) C3-7 cycloalkyl or C4-10 alkylcycloalkyl.
- 19. The compound of claim 18 wherein R4 is t-butyl.
- 20. The compound of claim 1 wherein R5 is H or C1-6 alkyl optionally substituted with 1-3 halogens.
- 21. The compound of claim 20 wherein R5 is H.
- 22. A compound of the formula
- 23. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 24. A method of inhibiting HCV NS3 protease comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 25. A composition comprising the compound of claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof and a pharmaceutically acceptable carrier.
- 26. The composition of claim 25 further comprising an additional immunomodulatory agent.
- 27. The composition of claim 26 wherein the additional immunomodulatory agent is selected from the group consisting of α-, β-, and δ-interferons.
- 28. The composition of claim 25 further comprising an antiviral agent.
- 29. The composition of claim 28 wherein the antiviral agent is selected from the group consisting of ribavirin and amantadine.
- 30. The composition of claim 25 further comprising an inhibitor of HCV protease other than the compound of claim 1.
- 31. The composition of claim 30 further comprising an inhibitor of a target in the HCV life cycle other than HCV NS3 protease.
- 32. The composition of claim 31 wherein the other target is selected from the group consisting of helicase, polymerase, metalloprotease and mixtures thereof.
- 33. Use of the composition of claim 25 for the manufacture of a medicament for treating a hepatitis C viral infection in a patient.
CROSS REFERENCE TO RELATED APPLICATION
[0001] The non-provisional application claims priority from the provisional application U.S. Ser. No. 60/382,104 filed May 20, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60382104 |
May 2002 |
US |